The Kirsten rat sarcoma viral oncogene homologue KRAS is among the most commonly
mutated oncogenes in human cancers, thus representing an attractive target for precision …

RAS is the most frequently mutated oncogene in human cancers, with mutations in about
30% of all cancers. RAS exists in three different isoforms (K-RAS, H-RAS and N-RAS) with …

Simple Summary KRAS is a gene that is commonly mutated in cancer, especially in
pancreatic, lung and colorectal cancers. Despite its importance, scientists have for many …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …

The nonreceptor protein tyrosine phosphatase SHP2 (encoded by PTPN11) integrates
growth and differentiation signals from receptor tyrosine kinases (RTKs) into the …

KRAS is frequently mutated in lung cancer. Whereas MAPK is a well-known effector pathway
of KRAS, blocking this pathway with clinically available MAPK inhibitors is relatively …

ABSTRACT KRAS is frequently mutated in a variety of cancers including lung cancer.
Whereas the mitogen-activated protein kinase (MAPK) is a well-known effector pathway of …

SHP2 is a protein tyrosine phosphatase that plays a critical role in the full activation of the
Ras-MAPK pathway upon stimulation of receptor tyrosine kinases, which are frequently …

RAS is one of the most well-known proto-oncogenes. Its gain-of-function mutations occur in
approximately 30% of all human cancers. As the most frequently mutated RAS isoform …

Mutant KRAS tumors are associated with poor outcomes, at least in part, due to decreased
therapeutic sensitivity. Here, we show that KRAS mutations are associated with resistance to …